France Cancer Pain Management Market Analysis Report [2022-30]

France Cancer Pain Management Market Analysis

$ 3999

France's Cancer Pain Management market is projected to grow from $179.3 Mn in 2022 to $251.1 Mn by 2030, registering a CAGR of 4.3% during the forecast period of 2022-2030. The main factors driving the growth would be government support and initiatives, the aging population, and increasing cancer incidence. The market is segmented by drug type and by disease. Some of the major players include Sanofi (FRA), Ethypharm (FRA), Grunenthal Pharma, Pfizer, Teva Pharmaceuticals, and Abbott.

ID: IN10FRHS002 CATEGORY: Healthcare Services GEOGRAPHY: France AUTHOR: Neha Davda

Buy Now

France Cancer Pain Management Market Executive Summary

France's Cancer Pain Management market is projected to grow from $179.3 Mn in 2022 to $251.1 Mn by 2030, registering a CAGR of 4.3% during the forecast period of 2022 - 2030. France spent $227 Bn on healthcare in 2020 or roughly $3,364 per person. In terms of health spending as a proportion of GDP and per person, France has historically fared better than the average for the EU. Prior to 2020, health spending increased at a rate that was relatively similar to that of the economy, but it did so more swiftly in response to the COVID-19 outbreak, which resulted in an 8% decrease in GDP.

Several well-identified acute and chronic pain syndromes are linked to cancer. Gene alterations affecting essential cell-regulatory proteins are the outcome of the complex and possibly lethal condition known as cancer. Such adjustments set off abnormal cell behaviour, which in turn causes unchecked cell growth and the consequent destruction of neighbouring normal tissues. By pressing on bones, nerves, and other areas of the body, these tumours put pressure on the body and cause pain. Cancer pain can also be felt while undergoing active cancer therapy, especially in more advanced stages of the disease.

france cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The French government has implemented a number of steps to increase access to cancer care, including the creation of cancer centres, the establishment of cancer screening programmes, and the provision of financial aid for patients. The cancer pain management market is anticipated to increase as a result of these activities, the ageing population and increasing cancer incidence in France.

Market Restraints

Despite having a highly developed healthcare system, access to specialised pain management therapy can be limited in France, especially in rural areas. Mainly, cancer pain management therapies have undesirable side effects that discourage patients from seeking care or restrict the usage of specific medications. The cancer pain management market's growth will be impacted by it.

Competitive Landscape

Key Players

Sanofi (FRA)
Ethypharm (FRA)
Grunenthal Pharma
Pfizer
Teva Pharmaceuticals
Abbott

Notable Recent Deals

December 2022: Sanofi and Innate Pharma announced the expansion of their partnership, with Sanofi licencing an NK cell engager programme from Innate's ANKETTM (Antibody-based NK Cell Engager Therapeutics) technology that targets B7H3. Additionally, Sanofi will have the choice to add up to two more ANKETTM targets. Sanofi will be in charge of all development, production, and commercialization following candidate selection.

Healthcare Policies and Regulatory Landscape

The French National Agency for Safety of Medicines and Health Products (ANSM) and the French National Authority for Health (HAS) are largely responsible for establishing the regulatory framework and healthcare policies for pain treatment in France. These organisations are in charge of establishing requirements for the safe and efficient application of pain management therapies as well as making sure that healthcare practitioners adhere to strict safety and quality requirements.

The National Plan for the Management of Chronic Pain and the construction of pain management clinics around the nation are only two of the policy efforts the French government has implemented to improve the management of chronic pain in France. Additionally, a variety of pain management therapies are covered by the French National Health Insurance System, including prescription drugs, physiotherapy, and some professional consultations. Patients might need to pay out of pocket for some treatments if reimbursement policies don't cover them entirely.

Reimbursement Scenario

The French National Health Insurance System (NHIS) is the main factor that determines how pain management therapies are reimbursed in France. Prescription drugs, physical therapy, and some professional consultations are among the pain management therapies covered by the NHIS. Although some therapies may require consumers to pay out of pocket, not all treatments are covered.

The French National Authority for Health (HAS), in cooperation with the French National Agency for Safety of Medicines and Health Products (ANSM), determines reimbursement rates for pain management procedures. The HAS also establishes the reimbursement rates for the therapies that are covered by the NHIS.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.